The International Myeloma Workshop Opens in Vienna
The International Myeloma Workshop Opens in Vienna image
The International Myeloma Workshop Opens in Vienna
Posted Sep 08, 2021

“Just imagine what we will see as we move these therapies up front,” pondered International Myeloma Society (IMS) President Nikhil Munshi about recently approved drugs moving up eventually to newly diagnosed patients as he opened the International Myeloma Workshop (IMW) in Vienna, Austria on September 8, 2021.

Diagnostic tests will also become better and more refined in disease management, leading Dr. Munshi to conclude that “MRD and expanded MRD will lead to a cure.”

Munshi believes that as many as 25% of patients today may be cured, but no tests exit to verify this estimate. “There’s a portion of patients that are not relapsing and we’re building on that.”

Noting the fundamental changes that have taken place since the last IMW in Boston, Dr. Munshi concluded that myeloma advances in the past decade and a half have been astounding. “Progress has truly been breathtaking” and has translated into better outcomes for myeloma patients everywhere, including:

  • Genetic characteristics linked to specific therapies
  • Factors that affect progression of high-risk disease
  • Identifying a “good” risk group with long survival prognoses
  • New technology in diagnostics and gene manipulation to improve therapy
  • Drug pathway resistance
  • The role of tests like MRD to speed up drug approval and create cures

This increased activity and knowledge is already paying dividends in the clinic. In addition to five new drug approvals in the past two years, Dr. Munshi cited the roles that MRD and expanded MRD as well as “the future promise of CAR T” therapy.

What’s the difference between the International Myeloma Workshop (IMW) and the American Society of Hematology (ASH) meetings?  Simply put, IMW looks at the the actual state of myeloma treatment today; ASH is mostly forward-looking, a time to report on studies about how things might change.

IMW is biannual, conducted by the International Myeloma Society (IMS) and attended by professionals who primarily treat or work with myeloma patients.  ASH is the annual professional meeting for all hematological conditions, myeloma being one of many topics covered.

Check the HealthTree Foundation website for more articles from this year’s IMW, which continues through September 11.

The author Greg Brozeit

about the author
Greg Brozeit

Greg Brozeit has been engaged in myeloma patient advocacy since 1998. He began working with the Myeloma Crowd in 2015. Prior to that, he consulted with Dr. Bart Barlogie at the University of Arkansas after working with the International Myeloma Foundation for 15 years, where he inaugurated the public policy advocacy program, patient support group outreach and IMF Europe, organizing more than 100 physician and patient education programs. He earned his BA in political science from Loyola University in New Orleans and lives in northeast Ohio.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Bristol Myers Squibb
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811